Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03626415 · ClinicalTrials.gov registry record · Phase 1
A Hepatic Impairment Study for PF-04965842.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03626415 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT03626415, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.
Interventions
- DRUG PF-04965842
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2019-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03626415
The ClinicalTrials.gov registry entry for NCT03626415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04965842 is the first listed.
NCT03626415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03626415 about?
NCT03626415 is a clinical study titled "A Hepatic Impairment Study for PF-04965842.". This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.
What is the current status of trial NCT03626415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-10-01. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03626415?
The interventions under investigation include: PF-04965842 (DRUG).
Who is sponsoring clinical trial NCT03626415?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.